{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:44:34Z","timestamp":1790073874505,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sumitomo Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40268-023-00416-8","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:02:53Z","timestamp":1684170173000},"page":"99-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma"],"prefix":"10.1007","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct02358395","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"Okusaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"416_CR1","unstructured":"International Agency for Research on Cancer and the World Health Organization. Globocan cancer statistics 2020: liver cancer factsheet. Available at: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/11-Liver-fact-sheet.pdf. Accessed 5 Sep 2022."},{"key":"416_CR2","unstructured":"Ministry of Health, Labour and Welfare. Vital statistics of Japan 2018. Available at: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/dl\/81-1a2en.pdf. Accessed 5 Sep 2022."},{"key":"416_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kudo","year":"2020","unstructured":"Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50:15\u201346. https:\/\/doi.org\/10.1111\/hepr.13438.","journal-title":"Hepatol Res"},{"key":"416_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. https:\/\/doi.org\/10.1038\/s41572-020-00240-3.","journal-title":"Nat Rev Dis Primers"},{"key":"416_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.486","volume":"7","author":"K Akada","year":"2019","unstructured":"Akada K, Koyama N, Taniguchi S, Miura Y, Aoshima K. Database analysis of patients with hepatocellular carcinoma and treatment flow in early and advanced stages. Pharmacol Res Perspect. 2019;7: e00486. https:\/\/doi.org\/10.1002\/prp2.486.","journal-title":"Pharmacol Res Perspect"},{"key":"416_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000367775","volume":"5","author":"M Kudo","year":"2016","unstructured":"Kudo M, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, et al. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016;5:190\u20137. https:\/\/doi.org\/10.1159\/000367775.","journal-title":"Liver Cancer."},{"key":"416_CR7","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep.25832","volume":"57","author":"S Roayaie","year":"2013","unstructured":"Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, et al. Resection of hepatocellular cancer \u22642 cm: results from two Western centers. Hepatology. 2013;57:1426\u201335. https:\/\/doi.org\/10.1002\/hep.25832.","journal-title":"Hepatology"},{"key":"416_CR8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378\u201390. https:\/\/doi.org\/10.1056\/NEJMoa0708857.","journal-title":"N Engl J Med"},{"key":"416_CR9","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 2.2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf. Accessed 5 Sep 2022."},{"key":"416_CR10","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/1078-0432.CCR-19-0302","volume":"25","author":"FEM Froeling","year":"2019","unstructured":"Froeling FEM, Swamynathan MM, Deschenes A, Chio IIC, Brosnan E, Yao MA, et al. Bioactivation of napabucasin triggers reactive oxygen species-nediated cancer cell death. Clin Cancer Res. 2019;25:7162\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0302.","journal-title":"Clin Cancer Res"},{"key":"416_CR11","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-20-1803","volume":"26","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe A, Kuboki Y, Shinozaki E, Hara H, Nishina T, Komatsu Y, et al. Multicenter phase I\/II trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503\/SCOOP trial). Clin Cancer Res. 2020;26:5887\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1803.","journal-title":"Clin Cancer Res"},{"key":"416_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s10147-021-01987-9","volume":"26","author":"H Taniguchi","year":"2021","unstructured":"Taniguchi H, Masuishi T, Kawazoe A, Muro K, Kadowaki S, Bando H, et al. Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer. Int J Clin Oncol. 2021;26:2017\u201324. https:\/\/doi.org\/10.1007\/s10147-021-01987-9.","journal-title":"Int J Clin Oncol"},{"key":"416_CR13","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2018.36.15_suppl.4010","volume":"36","author":"MA Shah","year":"2018","unstructured":"Shah MA, Sitara K, Lordick F, Bang Y-J, Tebbutt NC, Metges J-P, et al. The BRIGHTER trial: a phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol. 2018;36:4010. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.4010. (congress abstract).","journal-title":"J Clin Oncol"},{"key":"416_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/fon-2017-0406","volume":"14","author":"MB Sonbol","year":"2018","unstructured":"Sonbol MB, Bekaii-Saab T. A clinical trial protocol paper discussing the BRIGHTER study. Future Oncol. 2018;14:901\u20136. https:\/\/doi.org\/10.2217\/fon-2017-0406.","journal-title":"Future Oncol"},{"key":"416_CR15","doi-asserted-by":"publisher","first-page":"S1084","DOI":"10.1016\/annonc\/annonc709","volume":"32","author":"T Bekaii-Saab","year":"2021","unstructured":"Bekaii-Saab T, Okusaka T, Goldstein D, Oh D, Ueno M, Ioka T, et al. Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): results from the phase III CanStem111P study. Ann Oncol. 2021;32:S1084\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.794","journal-title":"Ann Oncol"},{"key":"416_CR16","doi-asserted-by":"publisher","first-page":"S220","DOI":"10.1016\/j.annonc.2021.05.011","volume":"32","author":"M Shah","year":"2021","unstructured":"Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, et al. FOLFIRI \u00b1 napabucasin in patients with previously treated metastatic colorectal cancer: overall survival results from the phase 3 CanStem303C study. Ann Oncol. 2021;32:S220. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.011. (congress abstract O-7).","journal-title":"Ann Oncol"},{"key":"416_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S2468-1253(18)30009-8","volume":"3","author":"DJ Jonker","year":"2018","unstructured":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:263\u201370. https:\/\/doi.org\/10.1016\/S2468-1253(18)30009-8.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"416_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111646","author":"C Lee","year":"2019","unstructured":"Lee C, Cheung ST. STAT3: an emerging therapeutic target for hepatocellular carcinoma. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11111646.","journal-title":"Cancers (Basel)."},{"key":"416_CR19","doi-asserted-by":"publisher","first-page":"597520","DOI":"10.3389\/fphar.2020.597520","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin reduces cancer stem cell characteristics in hepatocellular carcinoma. Front Pharmacol. 2020;11:597520. https:\/\/doi.org\/10.3389\/fphar.2020.597520.","journal-title":"Front Pharmacol"},{"issue":"15 Suppl","key":"416_CR20","doi-asserted-by":"publisher","first-page":"abstract 4077","DOI":"10.1200\/JCO.2017.35.15_suppl.4077","volume":"35","author":"BF El-Rayes","year":"2017","unstructured":"El-Rayes BF, Richards DA, Cohn AL, Richey SL, Feinstein T, Kunandra MN, et al. BBI608-503-103HCC: a phase Ib\/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC). J Clin Oncol. 2017;35(15 Suppl):abstract 4077.","journal-title":"J Clin Oncol"},{"key":"416_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.874","volume":"9","author":"N Noda","year":"2021","unstructured":"Noda N, Takagaki T, Yodo Y, Horibuchi Y, Iino S, Matsuki S, et al. Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT\/QTc interval in healthy volunteers. Pharmacol Res Perspect. 2021;9: e00874. https:\/\/doi.org\/10.1002\/prp2.874.","journal-title":"Pharmacol Res Perspect"},{"key":"416_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132.","journal-title":"Semin Liver Dis"},{"key":"416_CR23","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00280-020-04059-3","volume":"85","author":"A Kawazoe","year":"2020","unstructured":"Kawazoe A, Kuboki Y, Bando H, Fukuoka S, Kojima T, Naito Y, et al. Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020;85:855\u201362. https:\/\/doi.org\/10.1007\/s00280-020-04059-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"416_CR24","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/cpdd.961","volume":"10","author":"X Dai","year":"2021","unstructured":"Dai X, Karol MD, Hitron M, Hard ML, Goulet MT, McLaughlin CF, et al. Napabucasin drug\u2013drug interaction potential, safety, tolerability, and pharmacokinetics following oral dosing in healthy adult volunteers. Clin Pharmacol Drug Dev. 2021;10:824\u201339. https:\/\/doi.org\/10.1002\/cpdd.961.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"416_CR25","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1111\/cas.15068","volume":"112","author":"H Nakamura","year":"2021","unstructured":"Nakamura H, Takada K. Reactive oxygen species in cancer: current findings and future directions. Cancer Sci. 2021;112:3945\u201352. https:\/\/doi.org\/10.1111\/cas.15068.","journal-title":"Cancer Sci"},{"key":"416_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192\u2013203. https:\/\/doi.org\/10.1038\/s12276-020-0384-2.","journal-title":"Exp Mol Med"},{"key":"416_CR27","first-page":"181","volume":"2","author":"K Taniguchi","year":"2021","unstructured":"Taniguchi K, Tsugane M, Asai A. A brief update on STAT3 signaling: current challenges and future directions in cancer treatment. J Cell Signal. 2021;2:181\u201394.","journal-title":"J Cell Signal."},{"key":"416_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol Cancer. 2020;19:145. https:\/\/doi.org\/10.1186\/s12943-020-01258-7.","journal-title":"Mol Cancer"},{"key":"416_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020603","author":"M Tolomeo","year":"2021","unstructured":"Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020603.","journal-title":"Int J Mol Sci"},{"key":"416_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081191","author":"F Weinberg","year":"2019","unstructured":"Weinberg F, Ramnath N, Nagrath D. Reactive oxygen species in the tumor microenvironment: an overview. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11081191.","journal-title":"Cancers (Basel)."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00416-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00416-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00416-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:35:19Z","timestamp":1687797319000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00416-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["416"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00416-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"26 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by research funding from Sumitomo Pharma Co., Ltd. Development of napabucasin by Sumitomo Pharma Co., Ltd has now been suspended.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Takuji Okusaka has received grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Eisai Co., Ltd and Incyte Biosciences Japan GK; received grants from EP-CRSU Co., Ltd, Linical Co., Ltd, MSD K.K., and Syneos Healthfrom; and received personal fees from Bristol-Myers Squibb Company, Daiichi Sankyo Co., Ltd, Eli Lilly Japan K.K., Fujifilm Toyama Chemical Co., Ltd, Johnson & Johnson K.K., Mundipharma K.K., Nihon Servier Co., Ltd, Nippon Shinyaku Co., Ltd, Ono Pharmaceutical Co., Ltd, Pfizer Japan Inc., Taiho Pharmaceutical Co. Ltd, Teijin Pharma Ltd, and Yakult Honsha Co., Ltd. Shuichi Iino and Rie Kageyama are employees of Sumitomo Pharma Co., Ltd. Manabu Morimoto, Yuichiro Eguchi, and Shinichiro Nakamura have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with Good Clinical Practice ordinance, the ethical principles that have their origins in the Declaration of Helsinki, and all relevant national and international regulatory requirements. The protocol and all other study documentation were approved by the Institutional Review Board of each study center before enrollment of any patients into the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for study participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The research data underlying this study are subject to restrictions and cannot be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Takuji Okusaka, Manabu Morimoto, Yuichiro Eguchi, Shinichiro Nakamura, Shuichi Iino, and Rie Kageyama contributed to the study design and conduct, and to data collection. Data analysis was performed by Shuichi Iino and Rie Kageyama, and all authors contributed to data interpretation. All authors substantively reviewed each manuscript draft and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}